Fennec (FENC) Pharmaceuticals announced that Norgine Pharmaceuticals has commercially launched PEDMARQSI in Germany. “Until now, there have been no pharmacological interventions available to cancer patients in Germany to prevent ototoxicity, or permanent hearing loss, caused by treatment with cisplatin,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “We congratulate Norgine on making PEDMARQSI available to patients and healthcare providers in Germany and look forward to future launches in other major European markets.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue